What is Viome?
Viome operates at the intersection of health, technology, and personalized nutrition. The company specializes in at-home microbiome health tests, utilizing advanced AI and RNA sequencing to analyze an individual's unique microbiome. Based on these data-driven insights, Viome provides tailored nutrition recommendations and supplements designed to optimize health and combat chronic diseases. Their product suite includes various intelligence tests, such as the Full Body, Gut, and Oral Health Intelligence Tests, catering to a broad audience from individuals with specific health concerns to data-savvy consumers and health professionals. Viome's mission is to uncover the root causes of health issues and promote overall well-being through personalized, scientific approaches.
How much funding has Viome raised?
Viome has raised a total of $163M across 5 funding rounds:
Series A
$15M
Series B
$5.5M
Debt
$2M
Other Financing Round
$54M
Series C
$86.5M
Series A (2017): $15M with participation from BOLD CAPITAL PARTNERS and Khosla Ventures
Series B (2018): $5.5M led by Khosla Ventures and Physician Partners
Debt (2020): $2M supported by PPP
Other Financing Round (2021): $54M featuring Glico, Khosla Ventures, Physician Partners, WestRiver Group, and BOLD Capital Group
Series C (2023): $86.5M backed by BOLD Capital Group, Khosla Ventures, and WRG Ventures
Key Investors in Viome
BOLD Capital Group
BOLD Capital Group is a private investment firm specializing in early-stage technology platforms across healthcare and other sectors, offering minority investments and advisory services for capital raising and strategic planning.
Khosla Ventures
Khosla Ventures is a venture capital firm that provides funding and strategic advice to entrepreneurs focused on breakthrough technologies in areas such as AI, health, and sustainable energy.
WestRiver Group
WestRiver Group is an investment platform that directs capital to purpose-driven enterprises leveraging innovation to enhance societal well-being, focusing on the global innovation economy.
What's next for Viome?
With its latest major enterprise-level funding, Viome is strategically positioned to accelerate its growth and further innovate within the personalized health and longevity market. The substantial capital injection is expected to fuel advancements in their proprietary technology, expand their service offerings, and enhance their market reach. This investment signals strong confidence from backers in Viome's business model and its potential to disrupt traditional healthcare paradigms by offering data-driven, preventative health solutions. The company is likely to focus on scaling its operations, deepening its research into the microbiome's impact on health, and potentially exploring new therapeutic applications derived from its unique data insights.
See full Viome company page
